Clinical Trial Update: OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating OPT-302 in combination with ranibizumab for neovascular age-related macular degeneration has been terminated, with results posted in Ju…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• OPT-302
• Ranibizumab (ranibizumab)

Snippet

Sponsor: Opthea Limited | Conditions: Neovascular Age-related Macular Degeneration | Phase 3 | Status: TERMINATED | Results posted: 2025-07-22